Home
About Us
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.
Our Pipeline
Avalo’s lead asset is AVTX-009,
an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional product candidates which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Presentations
Recent News
Nov 12, 2024 7:00 am
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Nov 11, 2024 7:00 am
Avalo Therapeutics to Present at Upcoming Investor Conferences
